Irinotecan Hydrochloride Liposome

Phase 3Small molecule

Irinotecan Hydrochloride Liposome is one of 178 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

177

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine CarcinomaNot yet recruiting

Ewing SarcomaRecruiting

Colorectal CancerRecruiting

Gastric CancerNot yet recruiting

Small Cell Lung CancerRecruiting

ChemoradiotherapyRecruiting

Biliary Tract CarcinomaNot yet recruiting

Metastatic Biliary Tract CarcinomaNot yet recruiting

Hypofractionated RadiotherapyRecruiting

Neuroendocrine CarcinomaPhase 3

Not yet recruiting

Ewing SarcomaPhase 1

Recruiting

Colorectal CancerPhase 2

Recruiting

Gastric CancerPhase 3

Not yet recruiting

Small Cell Lung CancerPhase 3

Recruiting

ChemoradiotherapyPreclinical

Recruiting

Biliary Tract CarcinomaPreclinical

Not yet recruiting

Metastatic Biliary Tract CarcinomaPhase 2

Not yet recruiting

Hypofractionated RadiotherapyPhase 2

Recruiting

Competition

Competitive Landscape

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

38 2

Mfolfox6

Roche

Phase 3

5 3

Botensilimab

AAgenus Inc.

Phase 3

9 4

Calcium Folinate

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

3 5

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

2 6

Irinotecan Hydrochloride Liposome

Luye Pharma Group Ltd.

Phase 3

1 7

Folfirinox

PPhanes Therapeutics

Phase 3

1 8

Biological Check-up

UUniversity Hospital, Bordeaux

Phase 3

1 9

Trodelvy

Gilead

Preclinical

1 10

Ketalar

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Ewing Sarcoma

NCT06340204

Phase 2Recruiting

Colorectal Cancer

NCT06763029

N/ANot yet recruiting

Biliary Tract Carcinoma

NCT06463548

Q4 2027

Post-ApprovalNot yet recruiting

Gastric Cancer

NCT06499610

N/ARecruiting

Chemoradiotherapy

NCT06894797

Post-ApprovalNot yet recruiting

Neuroendocrine Carcinoma

NCT07014540

Clinical

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer

Recruiting·TTang-Du Hospital·Phase 4·NCT06467786·24 enrolled

Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

Recruiting· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 3·NCT06128837·686 enrolled

Biliary Tract Cancer2 trials

A Phase III Randomized Controlled Clinical Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07606599·398 enrolled

A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07582315·538 enrolled

Hypofractionated Radiotherapy1 trial

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Recruiting·FFudan University·Phase 2·NCT07183865·44 enrolled

Colorectal Cancer1 trial

Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

Recruiting·FFudan University·Phase 2·NCT06763029·36 enrolled

Metastatic Biliary Tract Carcinoma1 trial

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Not yet recruiting·BBa Yi·Phase 2·NCT06430827·20 enrolled

6 more indications

Neuroendocrine Carcinoma1 trial

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

Not yet recruiting·—·Phase 4·NCT07014540·45 enrolled

Ewing sarcoma1 trial

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Recruiting·PPeking University People's Hospital·Phase 1·NCT06340204·44 enrolled

Gastric Cancer1 trial

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

Not yet recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 4·NCT06499610·44 enrolled

Biliary Tract Carcinoma1 trial

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Not yet recruiting·YYunpeng Liu·N/A·NCT06463548·30 enrolled

Chemoradiotherapy1 trial

Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

Recruiting·PPeking University Cancer Hospital & Institute·N/A·NCT06894797·68 enrolled

Solid Tumor1 trial

A Phase Ib/ II Clinical Study to Evaluate the Safety and Efficacy of SYH2051 in Combination With Irinotecan Hydrochloride Liposome in Patients With Advanced Solid Tumors

Not yet recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Preclinical·NCT07911579·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Irinotecan Hydrochloride Liposome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Irinotecan Hydrochloride Liposome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Irinotecan Hydrochloride Liposome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Luye Pharma Group Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Luye Pharma Group Ltd.

Irinotecan Hydrochloride Liposome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Biliary Tract Cancer2 trials

Hypofractionated Radiotherapy1 trial

Colorectal Cancer1 trial

Metastatic Biliary Tract Carcinoma1 trial

Neuroendocrine Carcinoma1 trial

Ewing sarcoma1 trial

Gastric Cancer1 trial

Biliary Tract Carcinoma1 trial

Chemoradiotherapy1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News